A Phase 3 interventional study of Ferric Maltol and Ferrous sulfate in Anemia and Iron-deficiency, sponsored by Shield Therapeutics. Completed at 23 sites in 3 countries. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 464 studies in Anemia with a site in United States — 38 open to participants now, 58 under way, 18 of them phase 3. Anemia · United States.
Among the 464 studies in Anemia with a site in United States, this one is the 204th largest by enrollment of the 395 interventional ones that give a count, is one of 16 that started in 2021, is one of 114 in phase 3, and was the 402nd registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →38 of the 464 studies in Anemia with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 1 Month to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
464 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 71 · Phase 2 136 · Phase 3 122 · Phase 4 34
First in 1992; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 72 across the 395 interventional studies, 116 across the 50 observational. Of the 367 that completed or were terminated, 196 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 464 have an industry lead sponsor. The 10 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 4 studies filed under Anemia — fewer than ten, so there is no comparison to draw.
10 of the studies in Anemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06527391Phase 3University of MinnesotaCholine and Iron Deficiency | 2027-09-21 |
| NCT04747613Phase 3Novartis PharmaceuticalsLong-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | 2027-10-18 |
| NCT06106269Mayo ClinicOutcomes and Quality of Life Following Rectal Artery Embolization for Bleeding Internal Hemorrhoids | 2026-12 |
| NCT05340465University of WashingtonDarbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants | 2027-01-30 |
| NCT06788691Weill Medical College of Cornell UniversityLuspatercept for Clonal Cytopenias of Uncertain Significance | 2027-02 |
Add all 10 to your calendar (.ics) → With an account.
Among the 464 studies in Anemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liquid in children and adolescents aged 2 years to 17 years, and assess the safety and tolerability of ferric maltol oral suspension in children 1 month to less than 2 years, in the treatment of iron deficiency anaemia during the 12 weeks treatment period.
The study is a randomised, Open-label, Active-controlled, Multicentre, Comparative Study to Evaluate the Safety and Efficacy of Ferric Maltol (Iron (III)-Maltol Complex) (ST10) Oral Suspension Compared to Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, Incorporating a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years.
Approximately 110 male and female children from 1 month to 17 years of age, with iron deficiency anaemia. If less than 91 subjects in total have been randomized when 32 ferric maltol subjects have completed, then an interim analysis will be conducted.
Subjects aged 2 to 17 years will be 1:1 randomised to ferric maltol and ferrous sulfate, with 49 subjects in each arm. Subjects then will be further divided into 2 age groups: 2 yrs - 9 yrs and 10 yrs -17 yrs. A minimum of 18 subjects must be recruited into the 2 yrs - 9 yrs and 10 yrs - 17 yrs age groups and a minimum of 25% of either sex must be recruited.
A maximum of 12 subjects will be recruited in the 1 month to less than 2 years age group. They will only be assigned to the ferric maltol group, once there is evidence of absorption, of serum iron and elimination of maltol from the Pre-assignment PK samples by showing urine maltol return to baseline, or to a low level, confirming no accumulation of maltol or maltol glucuronide, they will continue on to the 12 weeks treatment phase.
Design: The study will comprise of the following stages:
Investigational Product Product: Ferric maltol oral suspension: oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension.
Ferric maltol oral suspension will be taken every morning and evening at least 30 minutes after a meal. Dosing will be supervised by the parent/legal guardian for children/adolescents throughout the treatment period and recorded on a dosing diary.
Ferric maltol bottles will be labelled for clinical trials use and each bottle will have a unique bottle number which will be utilised in the randomisation procedure.
A final eligibility evaluation must be conducted immediately prior to randomisation.
Reference safety information will be the Investigator Brochure.
Comparator therapy: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid or equivalent dose will be administered under this protocol. Dosing will be supervised by the parent/legal guardian for children/adolescents throughout the treatment period and recorded on a dosing diary.
Reference safety information will be the currently approved summary of product characteristics.
Statistical methods:
Safety and gastrointestinal tolerability will be compared between ferric maltol oral suspension and ferrous sulfate oral liquid via summaries of treatment emergent adverse events (TEAEs), treatment emergent serious AEs (TESAEs) and treatment-emergent AEs (TEAEs) leading to premature discontinuation of study drug.
Efficacy of ferric maltol will be assessed via the change in Hb concentration from baseline to week 12. If no interim analysis is conducted it will be based on a 95% two-sided confidence interval; If an interim analysis is conducted, a Pocock spending function will be used; the interim analysis will be based on a (100 - 3.45)% two sided confidence interval; if the study does not stop after the interim analysis, the final analysis will be based on a (100 - 2.57)% two sided confidence interval.
For the PK analysis, all analytes in serum will be summarised per PK day, for children and adolescents aged 1 month to 17 years receiving ferric maltol.
In addition, all analytes in urine will be summarised per PK day, for children aged 1 month to less than 2 years.
Full details of the statistical analysis, including the analysis of PK endpoints, will be specified in the statistical analysis plan (SAP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
thresholds define anaemia by age and gender:
Children (1 m - \< 5 yrs) \<11.0 g/dl Children (5 yrs - \< 12 yrs) \<11.5 g/dl Children (12 yrs) \<12.0 g/dl Female child (≥13 yrs) \<12.0 g/dl Male child (≥13 yrs) \<13.0 g/dl and
Ferritin thresholds define anaemia by:
ferritin \<30 µg/L, or ferritin \<50 µg/L with transferrin saturation (TSAT) \<20%, 4. Female subjects of must agree to use a highly effective method of (which includes complete abstinence) until study completion and for at least 4 weeks following their final study visit. Highly effective contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), a vasectomised partner and oral contraceptive medications.
The need for contraception and compliance with contraception requirements will be assessed at every visit for adolescent patients, and urine pregnancy testing will be performed at each visit for female subjects of childbearing potential.
Exclusion Criteria:
Subject with anaemia due to any cause other than iron deficiency, including, but not limited to,
a. Untreated or untreatable severe malabsorption syndrome
Subjects who have received prior to Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects aged 1 month to less than 2 years will enter a Pre-assignment phase: baseline urine samples are collected and subjects will take a single dose of 0.1 ml/kg ferric maltol suspension. Further 3 samples up to 12h will be taken. Subjects showing evidence of absorption, metabolism and elimination of maltol will enter the treatment phase and be assigned to the ferric maltol arm. The first 6 subjects screened will perform the pre-assignment PK phase. After review by the investigator, and medical monitors , if Maltol Glucuronide is shown to be adequately eliminated, timepoint 20-24 hrs (+ 4hrs) will not be performed on subsequent subjects. Subjects will be assigned to receive ferric maltol oral suspension and start the 0.1 ml/kg BID dose on V2 and continue for 7-10 days. On V3 they will perform the same PK assessments as on Pre-assignment PK visit.
Drug: Ferric Maltol
Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid. The first 12 subjects randomised to ferric maltol in each age sub-group (2 - 9 yrs, 10 - 17 yrs respectively) will enter a PK phase with 2 PK days. Following PK Day 2 subjects will continue until Week 12. Once the 18 subjects in each age subgroup have finished their PK visits, they will continue until week 12. Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID. Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period.
Drug: Ferric Maltol
Subjects aged 2-17 will be randomised 1:1 to receive ferric maltol oral suspension or ferrous sulfate oral liquid. Ferrous sulfate 125 mg/ml (25 mg elemental iron) or equivalent dose will be used for all children/adolescents. To maximise the iron replenishment for subjects within this group as well; aged 2 - 17 yrs will be dosed 6 mg/kg to the maximum of 4 ml BID. Subjects randomised to ferrous sulfate oral liquid will not need to complete the PK period.
Drug: Ferrous sulfate
Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.
Also known as: Feraccru, Ferric Trimaltol, ST10, ST10-01
Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle. Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Change in Hemoglobin Concentration
The change in Hb concentration from baseline to Week 12 is summarized based on the mITT Population for each treatment group using descriptive statistics summarized by mean, standard deviation, median, and range (minimum and maximum). The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
Time frame: From baseline to week 12.
Changes in Ferritin Concentration
Changes in ferritin concentration from baseline to week 12 summarised based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
Time frame: From baseline to week 12.
Change in Iron Concentration
Change in iron concentration from baseline to week 12 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
Time frame: From baseline to week 12.
Change in the Percentage of Transferrin Saturation
Change from baseline to Day 84 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
Time frame: From baseline to week 12.
Cmax for Plasma Maltol Glucuronide
Measured maximum plasma concentration (Cmax) (ng/mL) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Tmax for Plasma Maltol Glucuronide
Time to maximum plasma concentration (Tmax) (h) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
AUC0-t for Plasma Maltol Glucuronide
Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for plasma maltol glucuronide (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Cmax for Baseline Corrected Serum Iron
Measured maximum plasma concentration (Cmax) (μg/dL) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
Tmax for Baseline Corrected Serum Iron
Time to maximum plasma concentration (Tmax) (h) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
AUC0-t for Baseline Corrected Serum Iron
Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for baseline corrected serum iron (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
Time frame: PK parameters assessed at Day 1 (Visit 2) and Day 7-10 (Visit 3).
This was a multicenter study with a total of 23 clinical sites located in the United States(including Puerto Rico) and United Kingdom. A total of 65 patients were enrolled in the study.
| Milestone | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized |
|---|---|---|---|
| Started | 4 | 31 | 30 |
| Completed | 3 | 28 | 25 |
| Not completed | 1 | 3 | 5 |
| Withdrew: Withdrawal by subject | 1 | 1 | 4 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
The change in Hb concentration from baseline to Week 12 is summarized based on the mITT Population for each treatment group using descriptive statistics summarized by mean, standard deviation, median, and range (minimum and maximum). The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
| g/L | mITT Ferric Maltol Assigned | mITT Ferric Maltol | mITT Ferrous Sulfate |
|---|---|---|---|
| Change in Hemoglobin Concentration | 17.7 ± 13.61 | 12.5 ± 13.89 | 11.5 ± 13.97 |
Changes in ferritin concentration from baseline to week 12 summarised based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
| μg/L | mITT Ferric Maltol Assigned | mITT Ferric Maltol | mITT Ferrous Sulfate |
|---|---|---|---|
| Changes in Ferritin Concentration | 6.3 ± 8.74 | 8.1 ± 11.06 | 20.6 ± 30.97 |
Change in iron concentration from baseline to week 12 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
| μmol/L | mITT Ferric Maltol Assigned | mITT Ferric Maltol | mITT Ferrous Sulfate |
|---|---|---|---|
| Change in Iron Concentration | 1.07 ± 0.577 | 5.77 ± 8.518 | 3.64 ± 8.911 |
Change from baseline to Day 84 summarized based on the mITT Population for each treatment group. The Randomized/ITT Population is defined as all patients who were randomized/assigned to treatment arms. The mITT Population is defined as all patients in the ITT Population who received at least 1 treatment dose.
| Percentage of Transferrin Saturation | mITT Ferric Maltol Assigned | mITT Ferric Maltol | mITT Ferrous Sulfate |
|---|---|---|---|
| Change in the Percentage of Transferrin Saturation | 2.0 ± 0.00 | 7.7 ± 10.14 | 6.5 ± 12.39 |
Measured maximum plasma concentration (Cmax) (ng/mL) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| ng/mL | PK Population Ferric Maltol 15mg (2-9 y) Day 1 | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| Cmax for Plasma Maltol Glucuronide | 4350 ± NA | 6810 ± NA | 6420 ± NA | 4250 ± NA | 5940 ± NA | 8160 ± NA |
Time to maximum plasma concentration (Tmax) (h) for plasma maltol glucuronide after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| h | PK Population Ferric Maltol 15mg (2-9 y) Day 1 | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| Tmax for Plasma Maltol Glucuronide | 1.00 ± NA | 2.13 ± NA | 0.52 ± NA | 0.98 ± NA | 2.78 ± NA | 3.63 ± NA |
Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for plasma maltol glucuronide (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| hxng/mL | PK Population Ferric Maltol 15mg (2-9 y) Day 1 Subject analysis | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| AUC0-t for Plasma Maltol Glucuronide | 7670 ± NA | 12000 ± NA | 14600 ± NA | 5900 ± NA | 8070 ± NA | 16700 ± NA |
Measured maximum plasma concentration (Cmax) (μg/dL) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| μg/dL | PK Population Ferric Maltol 15mg (2-9 y) Day 1 | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| Cmax for Baseline Corrected Serum Iron | 87.0 ± NA | 40.0 ± NA | 119 ± NA | 96.5 ± NA | 21.0 ± NA | 364 ± NA |
Time to maximum plasma concentration (Tmax) (h) for baseline corrected serum iron after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| h | PK Population Ferric Maltol 15mg (2-9 y) Day 1 | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| Tmax for Baseline Corrected Serum Iron | 2.37 ± NA | 2.13 ± NA | 2.00 ± NA | 2.10 ± NA | 2.78 ± NA | 6.63 ± NA |
Area under the plasma concentration-time curve from pre-dose (time 0) to the time of last quantifiable plasma concentration for baseline corrected serum iron (AUC0-t) (hxng/mL) after a single dose of ferric maltol oral suspension on Visit 2 (PK Day 1) and after twice daily administrations for at least 6 days, on Visit 3 (PK Day 2) after a single morning dose. Because of the limitations of PK sampling in the pediatric patient population, data from multiple patients in the same treatment and age group had to be combined, using the naïve pooled approach, to achieve a complete set of observations over time for PK analysis. The data did not support PK parameters generation using noncompartmental analysis (NCA) without combining patients. Using validated PK software WinNonlin, the 'sparse sampling' option was utilized to treat the data as one virtual subject and thus the resulting data did not support reliable error estimates of the PK parameters.
| hxμg/dL | PK Population Ferric Maltol 15mg (2-9 y) Day 1 | PK Population Ferric Maltol 15mg (10-17 y) Day 1 | PK Population Ferric Maltol 30mg (10-17 y) Day 1 | PK Population Ferric Maltol 15mg (2-9 y) Day 7-10 | PK Population Ferric Maltol 15mg (10-17 y) Day 7-10 | PK Population Ferric Maltol 30mg (10-17 y) Day 7-10 |
|---|---|---|---|---|---|---|
| AUC0-t for Baseline Corrected Serum Iron | 64.4 ± NA | 60.1 ± NA | 374 ± NA | 100 ± NA | 1.93 ± NA | 1180 ± NA |
Collected over During the 12-week treatment period and within 2 weeks after receiving the last dose of the study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Maltol Assigned | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Ferric Maltol Randomized | 0/31 (0%) | 0/31 (0%) | 4/31 (12.9%) |
| Ferrous Sulfate Randomized | 0/30 (0%) | 0/30 (0%) | 3/30 (10%) |
| Event | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized |
|---|---|---|---|
| WheezingRespiratory, thoracic and mediastinal disorders | 1/3 | 0/31 | 0/30 |
| Event | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized |
|---|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/3 | 0/31 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 1/31 | 0/30 |
| TeethingGastrointestinal disorders | 1/3 | 0/31 | 0/30 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/3 | 1/31 | 0/30 |
| ConjunctivitisInfections and infestations | 1/3 | 0/31 | 0/30 |
| NauseaGastrointestinal disorders | 0/3 | 2/31 | 3/30 |
| PyrexiaGeneral disorders | 0/3 | 2/31 | 0/30 |
| Age, Customized(Participants) | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized | Total |
|---|---|---|---|---|
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 4 | 0 | 0 | 4 |
| Children (2-11 years) | 0 | 10 | 11 | 21 |
| Adolescents (12-17 years) | 0 | 21 | 19 | 40 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized | Total |
|---|---|---|---|---|
| Female | 3 | 23 | 22 | 48 |
| Male | 1 | 8 | 8 | 17 |
| Ethnicity (NIH/OMB)(Participants) | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 13 | 12 | 27 |
| Not Hispanic or Latino | 1 | 18 | 18 | 37 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Ferric Maltol Assigned | Ferric Maltol Randomized | Ferrous Sulfate Randomized | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 3 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 9 | 11 | 20 |
| White | 1 | 18 | 16 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Jun 2024, 31 months.
Results were first posted in Nov 2025, 1 year 5 months after primary completion.
Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 31 months is above that.
Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Shield Therapeutics